Written by Keen Meds · Reviewed by Licensed Clinical Providers · March 1, 2026
Key Insight: A 2026 meta-analysis pooling data from 41 randomized controlled trials found no statistically significant increase in cardiovascular events or prostate cancer risk with testosterone therapy, representing the most comprehensive evidence synthesis in the history of TRT research.
Scientific consensus on a medical question is not built from a single study or a single trial. It accumulates over time, as multiple independent research groups in different populations, with different methodologies and different follow-up periods, ask the same fundamental questions and arrive at consistent answers. The 2026 meta-analysis published in the International Journal of Impotence Research (IJIR) represents that accumulated consensus for testosterone replacement therapy. By synthesizing data from 41 randomized controlled trials -- the largest ever assembled for this question -- it provides the most statistically powerful and methodologically comprehensive safety evaluation of TRT in the history of the field. This article explains what the study found, why 41 RCTs together carry particular scientific weight, and what this means for men and providers evaluating testosterone therapy in 2026.
The Study: 41 Randomized Controlled Trials
The 2026 IJIR meta-analysis was conducted by systematically identifying all published randomized controlled trials of testosterone therapy that included data on cardiovascular outcomes or prostate outcomes. After applying inclusion and exclusion criteria based on study quality, population characteristics, and outcome definitions, 41 RCTs met the criteria for inclusion.
This number is notable in context. Prior major meta-analyses of TRT and cardiovascular safety had typically included ten to twenty trials. The Hudson 2022 Lancet IPD meta-analysis was landmark for its methodological rigor. The TRAVERSE trial provided the definitive single-trial cardiovascular RCT. The 2026 IJIR analysis expanded the scope further, incorporating trials across different formulations, different populations, different follow-up durations, and different geographic settings -- adding breadth that no single previous analysis could achieve.
The primary safety outcomes examined were major adverse cardiovascular events (MACE) -- the standard composite endpoint that includes non-fatal heart attack, non-fatal stroke, and cardiovascular death -- and prostate cancer incidence. These two outcomes have been the focus of the most significant safety concerns about testosterone therapy historically and were the appropriate primary endpoints for this analysis.
What 41 Trials Together Found
The pooled analysis across all 41 randomized controlled trials found no statistically significant increase in cardiovascular events compared to placebo groups. The MACE rate in testosterone-treated men did not differ significantly from the rate in placebo-treated men when the data from all 41 trials were combined.
This replicates and extends the TRAVERSE trial finding in a critically important way. TRAVERSE was a single large RCT of approximately 5,200 men with specific cardiovascular risk factors. The 2026 meta-analysis spans 41 trials with diverse populations -- younger men, older men, men with and without pre-existing cardiovascular disease, men on different formulations, men in different countries. Finding consistent cardiovascular safety across this breadth of data substantially reduces the likelihood that the null finding is population-specific or due to the particular characteristics of any one trial.
On prostate cancer, the meta-analysis similarly found no statistically significant increase in prostate cancer incidence in men receiving testosterone therapy compared to placebo. This addresses what has historically been one of the most significant concerns about TRT -- the saturation model of prostate cancer and testosterone, which hypothesized that higher testosterone levels would fuel prostate cancer growth. The current evidence across 41 trials does not support this hypothesis.
Why 41 RCTs Together Carry More Weight Than Any Single Trial
Understanding why a meta-analysis of 41 trials provides stronger evidence than any single trial requires understanding the concept of statistical power and the problem of type II error.
Every clinical trial has a sample size that determines its statistical power -- its ability to detect a real effect if one exists. A trial that is too small may fail to detect a true risk increase simply because it does not enroll enough patients to accumulate enough events. This is called a type II error: concluding that a treatment has no effect when it actually does.
When 41 independent trials are combined in a meta-analysis, the effective sample size becomes the sum of all participants across all trials. This dramatically increases statistical power. If a cardiovascular or prostate risk increase from testosterone therapy existed at any clinically meaningful magnitude, a pooled analysis of 41 RCTs would have sufficient power to detect it. The fact that it was not detected in this analysis means either the risk does not exist or it is so small that it is unlikely to be clinically meaningful.
Additionally, a consistent null result across 41 trials with different populations, formulations, durations, and settings eliminates many of the potential explanations for why any single trial might produce a null result by chance. The convergence of evidence from diverse sources substantially strengthens the inference.
What This Means in the Context of TRT's Regulatory History
The 2026 meta-analysis should be understood against the backdrop of TRT's regulatory and scientific history. In 2010, an RCT by Basaria and colleagues was stopped early due to excess cardiovascular events in testosterone-treated men. In 2013, the Vigen observational study raised similar concerns. These findings generated FDA safety reviews, prescribing label revisions, and significant clinical hesitancy about TRT.
The subsequent years saw a systematic effort to address those concerns with properly designed and powered research. The TRAVERSE trial (2023), the Hudson IPD meta-analysis (2022), the Cannarella VTE meta-analysis (2024), and now the 41-trial IJIR meta-analysis (2026) all contribute to a converging body of evidence that, in appropriately selected and monitored patients, testosterone therapy does not significantly raise cardiovascular or prostate cancer risk.
The FDA's removal of the testosterone black box warning related to cardiovascular risk in March 2025 reflects this evolving evidence base. Regulatory bodies do not remove safety warnings without substantial accumulated evidence. The 2026 meta-analysis is part of that accumulated record.
Prostate Safety: Addressing the Historical Concern
The prostate safety finding deserves particular attention because prostate cancer has been the most emotionally charged concern about testosterone therapy for decades. The concern originated from early prostate cancer research in the 1940s showing that castration (and the resulting testosterone elimination) caused prostate cancer regression. This led to the assumption that testosterone promoted prostate cancer growth.
Subsequent research, including Abraham Morgentaler's decades of work on the saturation model, has substantially revised this view. The saturation model proposes that androgen-sensitive prostate tissue reaches a saturation point at relatively low testosterone levels -- above that threshold, additional testosterone does not further stimulate prostate growth. Clinical data, including multiple RCTs and the TRAVERSE trial, have consistently not found elevated prostate cancer rates in men on TRT.
The 2026 meta-analysis of 41 RCTs provides the broadest randomized evidence base confirming this conclusion. Men with a history of treated prostate cancer or active prostate malignancy are still generally excluded from TRT -- this is a different clinical situation requiring oncological evaluation. But for men without prior prostate cancer and with appropriate PSA monitoring, the evidence does not support elevated prostate cancer risk from TRT.
Frequently Asked Questions
How does the 2026 meta-analysis relate to the TRAVERSE trial?
They are complementary but distinct. TRAVERSE was a single large RCT specifically designed to evaluate cardiovascular safety, with an average follow-up of about 33 months. The 2026 IJIR meta-analysis synthesizes 41 independent RCTs with diverse populations and formulations. Both find no significant cardiovascular risk increase. Together, they represent a robust, multi-source convergence of randomized evidence -- each addressing limitations the other has.
Does this meta-analysis mean testosterone therapy has zero cardiovascular or prostate risk?
No study, however large, can demonstrate absolute zero risk. The finding is that no statistically significant increase in cardiovascular events or prostate cancer incidence was detected across 41 randomized trials. This is the appropriate scientific conclusion: that the risk, if any, is not detectable at a clinically meaningful magnitude with the current evidence base.
Does the FDA's removal of the testosterone black box warning reflect this evidence?
The FDA's March 2025 removal of the cardiovascular risk language from testosterone prescribing information reflected the accumulated weight of evidence -- including the TRAVERSE trial and other data. The 2026 IJIR meta-analysis represents continued confirmation of that evidence base, published after the FDA action.
Should men with a history of prostate cancer receive testosterone therapy?
This is a nuanced clinical question that falls outside the scope of the 2026 meta-analysis. The trials included in the meta-analysis generally excluded men with active or recent prostate cancer. Men with a history of prostate cancer should discuss TRT specifically with their urologist or oncologist, as the risk-benefit analysis depends heavily on cancer stage, treatment history, and PSA status. The standard clinical contraindication for TRT is active or metastatic prostate cancer.
What This Means for Your Treatment Decisions
The 2026 IJIR meta-analysis of 41 randomized controlled trials represents the current scientific consensus: testosterone therapy, used appropriately in hypogonadal men with clinical monitoring, does not significantly raise cardiovascular or prostate cancer risk. This is as close to a definitive scientific conclusion as medicine produces. For men with confirmed testosterone deficiency and symptoms, the evidence strongly supports the safety of appropriately managed therapy.
Keen Meds connects you with licensed clinical providers for a telehealth evaluation and lab review. If your testosterone is clinically low, you may qualify for Testosterone Spray Rx.
